Skip to content

Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)

Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06195267
Acronym
PANDA
Enrollment
500
Registered
2024-01-08
Start date
2024-07-01
Completion date
2025-12-31
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Dissection, Systemic Inflammatory Response Syndrome, Cardiovascular Diseases (CVD)

Keywords

Systemic Inflammatory Response Syndrome

Brief summary

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acute phase of cardiovascular diseases will result in a reduced incidence of SIRS and MODS.

Interventions

The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.

Patients only received standard treatment and care.

Sponsors

The First Affiliated Hospital with Nanjing Medical University
CollaboratorOTHER
Beijing Anzhen Hospital
CollaboratorOTHER
Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset; * Patients with type A acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled. * The patients' age between 18 \ 90 years old. * Agree to participate in the study and sign the informed consent.

Exclusion criteria

* Patients allergic to sivelestat sodium; * Lactating women and pregnant women; * Patients with mental diseases, drug and alcohol dependence; * Refuse to participate in this study and refuse to sign the informed consent.

Design outcomes

Primary

MeasureTime frameDescription
The highest SOFA score of 7 days after surgery7 days after surgeryThe daily SOFA score after baseline was calculated for each patient on the basis of five organ systems: cardiovascular, respiratory, renal, hepatic, and coagulation systems. (Scores for each system range from 0 to 4, with higher scores indicating more severe organ-system dysfunction).

Secondary

MeasureTime frame
all-cause mortality30 days after surgery

Countries

China

Contacts

Primary ContactHong Liu, MD
dr.hongliu@foxmail.com+8618801281613
Backup ContactSheng Zhao, MD
zhaosheng0824@163.com02568303105

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026